EMD 503982

Drug Profile

EMD 503982

Latest Information Update: 31 Oct 2007

Price : $50

At a glance

  • Originator Merck KGaA
  • Class Antithrombotics
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arterial thrombosis; Venous thrombosis

Most Recent Events

  • 31 Oct 2007 Discontinued - Phase-I for Venous thrombosis in USA (PO)
  • 31 Oct 2007 Discontinued - Phase-I for Arterial thrombosis in USA (PO)
  • 08 Jun 2006 Phase-I clinical trials in Venous thrombosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top